Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Express Scripts
Dow
Mallinckrodt
Merck

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for CORT118335


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug CORT118335?

CORT118335 is an investigational drug.

There have been 9 clinical trials for CORT118335. The most recent clinical trial was a Phase 1 trial, which was initiated on November 4th 2020.

The most common disease conditions in clinical trials are Weight Gain, Non-alcoholic Fatty Liver Disease, and Fatty Liver. The leading clinical trial sponsors are Corcept Therapeutics, National Institute on Alcohol Abuse and Alcoholism (NIAAA), and The Scripps Research Institute.

There are five US patents protecting this investigational drug and fifty-seven international patents.

Recent Clinical Trials for CORT118335
TitleSponsorPhase
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)Corcept TherapeuticsPhase 1
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus PlaceboNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Phase 2
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus PlaceboThe Scripps Research InstitutePhase 2

See all CORT118335 clinical trials

Clinical Trial Summary for CORT118335

Top disease conditions for CORT118335
Top clinical trial sponsors for CORT118335

See all CORT118335 clinical trials

US Patents for CORT118335

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CORT118335 ⤷  Try it Free Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Try it Free
CORT118335 ⤷  Try it Free Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Try it Free
CORT118335 ⤷  Try it Free Pyrimidine cyclohexyl glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Express Scripts
Dow
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.